Are the Broad Institute’s CRISPR patents too broad?
The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.
21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.
18 May 2026 A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.